Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Pharmacology stubs
Retifanlimab
Другие языки:

    Retifanlimab

    Подписчиков: 0, рейтинг: 0

    Retifanlimab
    Monoclonal antibody
    Type Whole antibody
    Source Humanized
    Target Programmed cell death protein 1 (PD-1)
    Clinical data
    Trade names Zynyz
    Other names retifanlimab-dlwr
    License data
    Routes of
    administration    		 Intravenous
    ATC code
    Legal status
    Legal status
    Identifiers
    CAS Number
    DrugBank
    UNII
    KEGG
    Chemical and physical data
    Formula C6456H9934N1702O2032S46
    Molar mass 145381.13 g·mol−1

    Retifanlimab, sold under the brand name Zynyz, is an anti-cancer medication used for the treatment of Merkel cell carcinoma. Retifanlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.

    It was approved for medical use in the United States in March 2023.

    Medical uses

    Retifanlimab is indicated for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma.

    History

    The US Food and Drug Administration (FDA) evaluated the safety and efficacy of retifanlimab based on PODIUM-201 (NCT03599713), an open-label, multiregional, single-arm study evaluating 65 participants with metastatic or recurrent locally advanced MCC who had not received prior systemic therapy for advanced disease.

    The FDA granted the application for retifanlimab priority review, fast track, and orphan drug designations.

    Society and culture

    Names

    Retifanlimab is the international nonproprietary name.

    External links



    Новое сообщение